Cost-effectiveness of skin-check options, by a person's risk
For each band of 10-year melanoma risk, this page prices the care options (usual care, which is today's skin checks, GP checks at different intervals, specialist surveillance) in cost, QALYs and net monetary benefit, and shows how sure the result is. It is per person, for an average adult in the band: some already have a skin check every year and gain nothing from programme checks that only replace their own. It does not depend on how many people are at each risk. For national totals and workforce, use the planner.
Table A10.1 · Net monetary benefit by risk × action
| 10-yr risk | Usual care | 1× GP | GP 5-yr | GP 2-yr | GP annual | Spec 6-mo |
|---|---|---|---|---|---|---|
| 0.5% | $404.7k | $404.6k | $404.5k | $404.3k | $404.0k | $394.3k |
| 1.0% | $404.4k | $404.3k | $404.2k | $404.0k | $403.7k | $394.0k |
| 2.0% | $403.7k | $403.7k | $403.6k | $403.5k | $403.1k | $393.5k |
| 3.0% | $403.1k | $403.1k | $403.0k | $402.9k | $402.6k | $392.9k |
| 5.0% | $401.9k | $401.8k | $401.8k | $401.7k | $401.4k | $391.8k |
| 8.0% | $400.0k | $400.0k | $400.0k | $399.9k | $399.7k | $390.1k |
| 12.0% | $397.6k | $397.5k | $397.6k | $397.6k | $397.4k | $387.8k |
| 20.0% | $392.6k | $392.6k | $392.7k | $392.8k | $392.7k | $383.3k |
Shaded cell = the NMB-preferred action for that risk band at λ = $50.0k/QALY (with an indifference band, so it does not flicker). NMB = λ·QALY − Cost. Costs in 2026 AUD; benefit runs through melanoma deaths averted and less advanced disease, with penalties for overdiagnosis and for the biopsies and excisions that follow checks. Each cell is an average adult in the band, including those who already have a skin check every year. All values illustrative.
›Reference case and sources
Reference case (2026 prices, immunotherapy era). The comparator is usual care, not nothing: 37% of adults have a whole-body skin check every year (regular checkers) and the rest have none. National Sun Protection Survey 2016-17: 37% of adults 45-69 had a whole-body skin check in the past 12 months (Reyes-Marcelino 2021); 43% in the 45 and Up Study 2020 (Reyes-Marcelino 2026). Each of those checks is priced as a GP check ($86 each, MBS 1 Jul 2026) with its biopsies and excisions (Goldsbury 2024 per-check rates: 8.3% biopsy, 8.0% excision; $40 per check). Programme checks replace a regular checker's own checks one for one, so the gain comes from adults who are not checked today. What a check adds depends on how often checks happen: a check finds 30% of progressive melanomas before they would surface on their own with 5-yearly checks, 55% with 2-yearly, 72% with yearly and 84% with 6-monthly checks. In proportion to that share, stage II or later melanomas fall. Overdiagnosed in situ and stage I melanomas rise with the share of overdiagnosed melanomas found, which is higher because they stay detectable for longer (72% with 5-yearly and 93% with yearly checks; a mean of 10 years is an assumption). The sizes are calibrated to Australian studies of adults whose skin had been examined against adults whose skin had not. Aitken 2010 (Int J Cancer 126:450-8): whole-body clinical skin examination in the 3 years before diagnosis; melanomas 1.5 mm or thicker (two thickness groups pooled), odds ratio 0.74 (0.61-0.90). Examined adults taken to have 0.55 checks a year (Janda 2004: 11% examined in 12 months, 20% in 3 years). Aitken 2010: odds ratio 1.38 (1.22-1.56) for melanomas 0.75 mm or thinner and 0.93 (0.79-1.10) for 0.76-1.49 mm; combined 1.29 for melanomas under 1.5 mm (those 0.75 mm or thinner taken as 80%). Whiteman 2022 (Br J Dermatol 187:515-22), QSkin: in situ melanoma 1.45 (1.09-1.92) times as common in adults whose skin was examined by a doctor in the previous 3 years. A melanoma found earlier is found in situ or at stage I (50% in situ, an assumption). Melanomas diagnosed under usual care follow Australian registries (Australian Cancer Atlas 2010-2019 (persons): 165,641 in situ and 134,543 invasive melanomas), with the overdiagnosed shares of Lindsay 2024, and each overdiagnosed melanoma is costed at the price of its stage. The 6-monthly specialist option is priced at a high-risk clinic visit (Watts 2017) and valued as two checks a year, with no extra effect for its photography and dermoscopy. Melanomas detected in the 10-year programme carry lifetime consequences, all discounted to programme start: treatment at the stage found (surgery, sentinel node biopsy, imaging and, for stage III, adjuvant immunotherapy), an advanced-melanoma episode (immunotherapy or targeted therapy) for each stage IV diagnosis or relapse, end-of-life care, and QALYs lost to melanoma death, to time lived with advanced melanoma, to overdiagnosis and to each biopsy or excision. Survival is 10-year melanoma-specific survival by stage, calibrated so that melanoma deaths per invasive melanoma diagnosed under usual care are 8.3% (Australian melanoma deaths ÷ invasive diagnoses, AIHW). Costs are from the health-system perspective (government plus average patient contributions) at published PBS prices, an upper bound; the Workforce Lab cost panel shows the pre-immunotherapy era, the government perspective and drug discounts. The stage-shift benefit uses the stage mix of progressive melanomas (overdiagnosed lesions removed) and is scaled for lead time.
Cost-effectiveness acceptability curve
The probability that the NMB-preferred compound policy is cost-effective vs usual care, across willingness to pay, from 600 shared-input-draw simulations, with each risk band weighted by the people in it. It stays below 1 by design: with small per-person QALY differences, the decision is genuinely uncertain.
At λ = $50k/QALY, the compound policy is cost-effective vs usual care in 42% of simulations. Against usual care, 26% cost more and gain QALYs (north-east), 29% save money and gain QALYs (south-east: dominant), 36% cost more and lose QALYs (north-west: dominated) and 9% save money but lose QALYs (south-west). With 600 simulations the percentage is accurate to about 3 points either way. Illustrative; the definitive uncertainty analysis is Policy1-Melanoma's.
Regional deliverability of the recommended policy
The NMB-preferred policy priced above assumes the workforce exists. Here it is checked against each SA4's actual workforce, with the specialist tier checked against dermatologist capacity rather than combined GP and dermatologist capacity. Policy1-Melanoma does not model this regional variation; ATOF adds it.
At this willingness to pay the NMB-preferred policy is mostly usual care or infrequent checks, so it is deliverable everywhere. Raise λ (or look at higher-risk bands) to see where surveillance demand outruns the regional workforce.
A capacity-infeasible region is an investment gap, not a reason to under-screen it: the clinically preferred policy is unchanged; what is shown is the workforce (or teledermatology throughput) needed to deliver it, and how long that takes on the projected workforce trend per person aged 40+ (dermatologists +1.2% a year, GPs −0.3% a year). A gap that the trend does not close is shown as "not on current trends". Illustrative; SA4 is coarse and averages over dermatologist deserts within a region.